Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Citalopram hydrobromide
Cat. No.:
OB0225LY-0410
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
Citalopram hydrobromide is a selective 5-HT reuptake inhibitor (SSRI) used primarily to modulate neurotransmission.
Synonym:
Lu 10-171; Nitalapram HBr; Bonitrile HBr; XU-62-320; Lu 10-171 HBr; Citalopram HBr; 59729-32-7; 1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile hydrobromide
CAS No.:
59729-32-7
Compound CID:
77995
Formula:
C20H22BrFN2O
Formula Weight:
405.304
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Citalopram hydrobromide can be used in neuroscience research to explore its role in mood regulation and anxiety symptom relief.
Library Information
Targets:
5-HT receptor; Serotonin transporter
Pathways:
Autophagy; GPCR/G protein; Neuronal signaling
Plate Number:
AOCL-6
Plate Location:
c6
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
55 mg/mL; 135.7 mM
Water Max Solubility:
4 mg/mL; 9.9 mM
Ethanol Max Solubility:
6 mg/mL; 14.8 mM
